Lifeline BioTechnologies - correction:
This article was originally published in Clinica
Executive Summary
Lifeline BioTechnologies has pointed out that its First Warning System for breast cancer detection is likely to be used as an adjunct to mammography and is not intended as an alternative to the technique as stated in Clinica No 833, p 16. It added that while physician and patient acceptance of the technique is a major barrier to market entry, it is confident that if results from upcoming trials are equivalent to earlier studies, the FDA will approve the device.